Bleeding risk after TAVI in Asian cohort

- Masanori Yamamoto
- Toyohashi/Nagoya/Gifu heart center
- Division of cardiology

Potential conflict of interest


Speaker's name : Masanori Yamamoto


✓ I have the following potential conflicts of interest to declare:

Clinical proctors, Receipt of honoraria or consultation fees: Edwards (TAVI), Medtronic (TAVI), Abbott (TAVI, TEER), Boston (LAAC)

Aging society in Asia population

The optimal medical therapy is dynamically changed during the long life





Risk benefit balance


Antithrombotic therapy

Bleeding



Stroke, MI prevention

East Asia paradox



- Bleeding risk in white individuals
- ---- Bleeding risk in East Asian individuals
- Ischaemic risk in white individuals
- --- Ischaemic risk in East Asian individuals

Asian: low ischemic risk, but high bleeding risk

Nat Rev Cardiol. 2014 Oct;11(10):597-606.

J-HBR Criteria



Circulation Journal Circ J 2020; 84: 831-865 doi:10.1253/circj.CJ-19-1109 JCS GUIDELINES

JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease

Masato Nakamura; Kazuo Kimura; Takeshi Kimura; Masaharu Ishihara; Fumiyuki Otsuka; Ken Kozuma; Masami Kosuge; Toshiro Shinke; Yoshihisa Nakagawa; Masahiro Natsuaki: Satoshi Yasuda; Takashi Akasaka; Shun Kohsaka; Kazuo Haze; Atsushi Hirayama


Post PCI J-HBR : 64% (CREDO-Kyoto Registry Cohort-3)



Number 2514, average about 85 years old Patients after TAVI

HBR rates 91.4% ! !

Mizutani K, et al. EHJ open 2022





Abbreviations: ARC, Academic Research Consortium; HBR, high bleeding risk; TAVR, Transcatheter Aortic Valve Replacement

Poor prognosis in patients with HBR




Figure 2 Incidence of mortality. (A) The mortality rate in the entire patient population is shown. (B) The mortality rates are compared between patients at high-bleeding risk (HBR; HBR group) and the non-HBR group. (C) The mortality rates are compared between patients in the HBR low-, intermediate-, and high-risk groups.




Mizutani K, et al. EHJ open 2022

Late bleeding after TAVI (in elderly Asia cohort)

Cumulative incidence	0.05 -	leeding —Ischemic stroke Dverall P < 0.001		Major bleeding schemic stroke	4% eeding 4% coke
	0.00 0 Number at risk	365	730	1095 Days after TAV	D
All bleeding	2518	2129	1091	372	n
Ischemic stroke	2518	2171	1120	381	
Major bleeding	2518	2153	1107	377	
Minor bleeding	2518	2166	1121	382	
	Cumulative rates				
All bleeding	0.0%	3.6%	6.1%	7.4%	
Ischemic stroke	0.0%	1.1%	2.1%	3.4%	
Major bleeding	0.0%	2.5%	4.2%	5.2%	
Minor bleeding	0.0%	1.2%	1.7%	2.5%	



Yamamoto M, et al. JACC ASIA 2022




(A) The phase of late bleeding evens after transcatheter aortic valve replacement (TAVR) was calculated. The late bleeding events occurred from early to late phase after TAVR. (B) The detailed cause of bleeding information was investigated. The main cause of late bleeding was of gastrointestinal (GI) origin. The second cause of bleeding was hemorrhagic stroke that mainly associated with major bleeding. The other causes of bleeding were trauma, cancer, lung, and other organs including the eye, nose, and the genitourinary system.



Yamamoto M, et al. JACC ASIA 2022

Impact of late bleeding after TAVI on mortality




Bleeding risk (OCEAN data)


TABLE 4 Multivariate Analysis for the Association Between Late Bleeding and Clinical Findings

		Multivariate Analys	is
Explanatory Variables	OR	95% CI	P Value
Baseline characteristics			
Age (per 1 y)	1.01	0.98-1.04	0.60
Male	1.25	0.86-1.82	0.25
High CFS(\geq 4)	1.55	1.05-2.28	0.027
NYHA functional class III/IV (for I/II)	1.58	1.09-2.27	0.015
Pulmonary disease	1.41	0.96-2.07	0.084
Liver disease	1.93	0.92-4.07	0.084
Active cancer	1.87	0.98-3.54	0.057
Low platelet count (<14.9 \times 10 ⁴ /µL)	1.94	1.36-2.77	<0.00
Procedural bleeding complications	0.92	0.61-1.40	0.70

A. All bleeding between OAC and non OAC


B. All bleeding between AF and non AF





Japanese sub-analysis (OCEAN cohort)

DOAC is equivalent for VKA in Asian elderly cohort




Days since randomization

Data from OCEAN-LAAC within 45 days

The OCEAN-LAAC registry

N = 548





Risk benefit balance in elder patients

Antithrombotic therapy

Bleeding



Stroke, MI prevention

TABLE 4 Multivariate Analysis for the Association Between Late Bleeding and Clinical Findings

		Multivariate Analys	is
Explanatory Variables	OR	95% CI	P Value
Baseline characteristics			
Age (per 1 y)	1.01	0.98-1.04	0.60
Male	1.25	0.86-1.82	0.25
High CFS(\geq 4)	1.55	1.05-2.28	0.027
NYHA functional class III/IV (for I/II)	1.58	1.09-2.27	0.015
Pulmonary disease	1.41	0.96-2.07	0.084
Liver disease	1.93	0.92-4.07	0.084
Active cancer	1.87	0.98-3.54	0.057
Low platelet count (<14.9 \times 10 ⁴ /µL)	1.94	1.36-2.77	<0.001
Procedural bleeding complications	0.92	0.61-1.40	0.70

Abbreviations as in Table 1.